API
< Back to all clusters
[BUSINESS] · Poland · 4 sources

started · updated

Poland pharmacy market faces regulatory shifts and heavy fines

The Polish pharmaceutical market is undergoing significant structural changes driven by new legislation and regulatory enforcement. A recent parliamentary meeting focused on drug accessibility and pricing, highlighting the impact of the Office of Competition and Consumer Protection (UOKiK) imposing over 900 million PLN in fines on major wholesalers, including Farmacol, Neuca, and Świat Zdrowia, for participating in unlawful agreements.

Legislative updates are also transforming the sector. A new law lifting the ban on pharmacy advertising has been passed, though it introduces substantial financial risks. Penalties for non-compliance can reach 1 million PLN per violation point, a measure that critics suggest may disproportionately impact large pharmacy chains.

Additionally, discussions continue regarding the “Pharmacy for a Pharmacist” regulations and the potential for a new “prescription law” to further alter how pharmacies operate. Experts, including Marek Tomków, President of the Supreme Pharmaceutical Council, have noted that while the lifting of advertising bans is a major development, the lack of precise definitions for prohibited marketing practices remains a concern.

Entities

Farmacol · Neuca · Office of Competition and Consumer Protection · Poland · Supreme Pharmaceutical Council